Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stake Lessened by Oppenheimer Asset Management Inc.

Oppenheimer Asset Management Inc. lessened its stake in Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 8.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,710 shares of the company’s stock after selling 6,002 shares during the period. Oppenheimer Asset Management Inc. owned about 0.84% of Global X Genomics & Biotechnology ETF worth $694,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Atria Investments Inc bought a new stake in shares of Global X Genomics & Biotechnology ETF in the third quarter worth $122,000. Corrado Advisors LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 3.0% in the third quarter. Corrado Advisors LLC now owns 64,224 shares of the company’s stock worth $723,000 after purchasing an additional 1,894 shares during the period. James J. Burns & Company LLC boosted its holdings in Global X Genomics & Biotechnology ETF by 6.0% in the third quarter. James J. Burns & Company LLC now owns 18,293 shares of the company’s stock worth $207,000 after purchasing an additional 1,038 shares during the period. Centaurus Financial Inc. acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter worth $146,000. Finally, Sanctuary Advisors LLC acquired a new position in Global X Genomics & Biotechnology ETF in the second quarter worth $590,000. Institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Price Performance

Global X Genomics & Biotechnology ETF stock opened at $9.62 on Tuesday. The company has a market cap of $70.32 million, a PE ratio of -4.11 and a beta of 1.03. The company has a fifty day moving average price of $10.84 and a two-hundred day moving average price of $10.86. Global X Genomics & Biotechnology ETF has a 12 month low of $9.55 and a 12 month high of $12.53.

Global X Genomics & Biotechnology ETF Company Profile

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.